This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Prostamax (20 mg Vial)
Prostamax is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro / KEDP) derived from prostate tissue peptide complex research[1][2]. Short peptides of this class have been studied for their ability to modulate gene expression through epigenetic interactions with chromatin and histones[3][4].
Quick Reference
What is Prostamax?
Research overview based on the cited scientific literature.
• Goal: Support prostate tissue health and function through bioregulatory peptide signaling[1][2].
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 2 weeks.
Storage Instructions
Proper storage preserves peptide quality[8].
• Lyophilized (shortterm): Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
• Lyophilized (longterm): Store at −20 °C (−4 °F) for extended stability.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~2 weeks and avoid freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is Prostamax studied?
Prostamax (KEDP) belongs to the class of short bioregulatory peptides studied by Khavinson and colleagues. These tetrapeptides are proposed to modulate gene expression through epigenetic mechanisms, interacting with chromatin structure and histone proteins[3][4]. In aged human lymphocytes, KEDP has been observed to cause pericentromeric chromatin decondensation, potentially reactivating suppressed genes[3]. Preclinical rat models of prostatitis showed that IM administration of KEDP reduced inflammatory markers and helped prevent fibrotic changes in prostate tissue[1][2].
What does the research report about Prostamax?
Observations from preclinical literature (no published human trials).
• In rat prostatitis models, IM KEDP administration reduced inflammation and supported tissue normalization over treatment periods of 15–60 days[1].
• Studies in benign prostatic hyperplasia (BPH) models showed favorable effects on prostate weight and histological parameters[2].
• Short bioregulatory peptides of this class generally show favorable tolerability profiles in preclinical work[4].
• Potential for mild injectionsite reactions (redness, tenderness) as with any IM administration; rotate sites to minimize.
• Note: Human clinical trial data are not yet published; dosing is extrapolated from animal models.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on Prostamax?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
